Cadrenal Therapeutics Presents New Trial Data At ISHLT Conference Demonstrating The Importance Of Anticoagulation Quality In LVAD Patients; The ARIES-HM3 Clinical Study Was Sponsored By Abbott

Author: Benzinga Newsdesk | June 03, 2024 09:16am

Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor correlated in the ARIES-HM3 trial with better patient outcomes

PONTE VEDRA, Fla., June 3, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking presentation at the International Society for Heart & Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions.

Posted In: ABT CVKD